ConSynance Differentiates NASH Asset To Charm China
Executive Summary
Dr. Shuang Liu, president and co-founder of ConSynance Therapeutics, talks with Scrip’s Brian Yang about the US-based startup's plans to develop and commercialize in China its assets for indications including NASH.